425: VERAXA & Secarna Form AOC Alliance for Autoimmune Therapies

VERAXA Biotech and Secarna Pharmaceuticals announce a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases.

Summary

• VERAXA Biotech and Secarna Pharmaceuticals GmbH & Co. KG have initiated a strategic research collaboration to develop next-generation Antibody Oligonucleotide Conjugates (AOCs).
• The partnership aims to create novel targeted therapies for autoimmune and chronic immune diseases.
• Secarna will utilize its proprietary, AI-empowered OligoCreator platform to identify promising oligonucleotide candidates, including antisense oligonucleotides (ASOs) and siRNA strategies.
• VERAXA will employ its technology suite, including its click chemistry conjugation platform, to design and generate highly efficacious, uniform, and safe AOCs.
• AOCs combine the specificity of monoclonal antibodies with the functional versatility of oligonucleotides, enabling targeted delivery to disease-relevant cells.
• VERAXA Biotech is a proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH), with the business combination agreement signed on April 22, 2025.

Sentiment

Score: 8

Explanation: The announcement of a strategic collaboration to develop a novel class of targeted therapies (AOCs) for significant disease areas (autoimmune and inflammatory diseases) is a strong positive. It expands VERAXA's therapeutic modalities and leverages complementary technologies, indicating growth and innovation. The ongoing de-SPAC process, while carrying risks, is also a positive step towards public listing and potential capital access.

Positives

• The strategic collaboration combines Secarna's expertise in oligonucleotide therapeutics with VERAXA's antibody conjugation technology, creating a powerful synergy.
• The partnership aims to unlock novel targeted therapies for autoimmune and chronic immune diseases, addressing high unmet medical needs.
• AOCs offer significant advantages by delivering therapeutic oligonucleotides directly to disease-relevant cells, enhancing treatment efficacy and minimizing off-target effects.
• Secarna's AI-empowered OligoCreator platform is expected to greatly expedite the drug discovery process, from target selection to therapeutic development.
• The alliance highlights the versatility of VERAXA's technology suite and its ability to tackle opportunities with complementary partners beyond its primary R&D focus in oncology.
• AOCs represent a very attractive additional therapeutic modality for VERAXA, expanding its pipeline and market potential.

Risks

• Known and unknown risks, including those indicated in Voyager's SEC filings, particularly under 'Risk Factors'.
• Uncertainties, assumptions, and other factors beyond Voyager's or VERAXA's control that are difficult to predict.
• Actual results may differ materially and adversely from those expressed or implied in any forward-looking statements.
• The occurrence of any event, change, or circumstances that could lead to the termination of the Business Combination Agreement.
• The outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination.
• Inability to complete the Business Combination due to failure to obtain shareholder consents, secure financing, or satisfy other closing conditions.
• Delays in obtaining, adverse conditions contained in, or inability to obtain necessary regulatory approvals for the Business Combination.
• Changes to the proposed structure of the Business Combination required by laws, regulations, or as a condition for regulatory approval.
• Discrepancies in projections, estimates, and forecasts of revenue, financial, and performance metrics, market opportunity, and estimated implied enterprise value of VERAXA.
• VERAXA's ability to scale and grow its business, source and retain talent, and manage its cash position post-Business Combination.
• The ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination.
• The risk that the Business Combination disrupts current plans and operations of VERAXA.
• Inability to recognize the anticipated benefits of the Business Combination, potentially affected by competition, growth management, maintaining key relationships, and retaining management and key employees.
• Costs related to the Business Combination.
• Changes in applicable laws, regulations, political, and economic developments.
• The possibility that VERAXA may be adversely affected by other economic, business, and/or competitive factors.
• VERAXA's estimates of expenses and profitability.
• Failure to realize estimated shareholder redemptions, purchase price, and other adjustments.

Future Outlook

The collaboration aims to unlock novel targeted therapies for autoimmune and chronic immune diseases. VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. Upon closing of the Business Combination Agreement, VERAXA is expected to become a publicly traded company listed on NASDAQ. The alliance highlights the versatility of VERAXA's technology suite and the range of opportunities it can tackle with partners, with AOCs representing a very attractive additional therapeutic modality. The combination of platforms is expected to open up a wide range of potential therapeutic applications in immunological diseases.

Management Comments

• Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA: "Today's alliance with Secarna highlights once more the versatility of our technology suite and the range of opportunities we can tackle with partners that are complementary to our R&D focus in oncology. AOCs represent a very attractive additional pocket in our industry where our expertise and antibody conjugation technology can enable unique therapeutic modalities. We are thrilled to partner with Secarna, a renowned expert in the field of developing oligonucleotide-based therapies."
• Konstantin Petropoulos, Ph.D., CEO of Secarna Pharmaceuticals: "We are truly excited to collaborate with VERAXA on this new class of highly targeted therapeutics. The combination of our oligonucleotide platform with VERAXA's complementary ADC technologies, together with our mutual expertise in discovering and developing best-in-class therapeutics, will open up a wide range of potential therapeutic applications in the field of immunological diseases."

Industry Context

The biopharmaceutical industry is increasingly focused on developing targeted therapies to improve efficacy and reduce off-target effects, a trend exemplified by the development of Antibody Oligonucleotide Conjugates (AOCs). Strategic collaborations, like this one between VERAXA and Secarna, are a common and effective strategy for companies to combine specialized technological platforms and accelerate drug discovery in complex disease areas such as immunology. Furthermore, VERAXA's ongoing de-SPAC process with Voyager Acquisition Corp. reflects a broader trend of private biotech companies seeking public market access through SPAC mergers, particularly in high-growth sectors requiring significant capital for R&D and clinical development.

Stakeholder Impact

• Shareholders of Voyager Acquisition Corp. (VACH) may see potential value creation from the strategic collaboration and the successful completion of the Business Combination, but also face risks associated with the merger and future performance of the combined entity.
• Future shareholders of VERAXA Biotech will gain exposure to an expanded therapeutic pipeline, including novel AOCs, and strategic partnerships in the immunology space.
• Patients suffering from autoimmune and chronic immune diseases could benefit from the development of next-generation targeted therapies with enhanced efficacy and reduced off-target effects.
• Employees of VERAXA and Secarna may experience new opportunities and projects arising from the collaboration and expanded R&D efforts.
• Investment professionals will find new avenues for analysis and potential investment in the biotech sector, particularly concerning targeted therapies and de-SPAC transactions.

Next Steps

• Secarna will leverage its OligoCreator platform to identify promising oligonucleotide candidates.
• VERAXA will use its click chemistry conjugation platform to design and generate AOCs.
• VERAXA will continue advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development.
• Voyager and/or VERAXA intend to file relevant materials with the SEC, including a Registration Statement and proxy statement/prospectus, in connection with the Business Combination.
• Voyager's stockholders will vote on the proposed Business Combination.
• Completion of the Business Combination Agreement is expected to result in VERAXA becoming a publicly traded company on NASDAQ.

Key Dates

Recommendation

The strategic collaboration between VERAXA and Secarna Pharmaceuticals to develop next-generation Antibody Oligonucleotide Conjugates (AOCs) for autoimmune and inflammatory diseases is a positive development, expanding VERAXA's therapeutic modalities beyond oncology and leveraging Secarna's advanced oligonucleotide platform. This partnership enhances the long-term growth potential and diversification of VERAXA's pipeline. However, the company is still in the process of its de-SPAC acquisition by Voyager Acquisition Corp., which carries inherent risks including financing, regulatory approvals, and market acceptance post-merger. While the collaboration is promising, the overall investment thesis is still subject to the successful completion of the business combination and the early-stage nature of the AOC development. Therefore, a 'hold' recommendation is appropriate, awaiting further clarity on the merger completion and initial progress of the AOC program.

Keywords

VERAXA Biotech, Secarna Pharmaceuticals, Voyager Acquisition Corp, Antibody Oligonucleotide Conjugates, AOCs, OligoCreator, click chemistry, autoimmune diseases, inflammatory diseases, biotechnology, pharmaceuticals, SPAC, de-SPAC, strategic collaboration, drug discovery, targeted therapies, ASOs, siRNA